Testing all patients in our cohort for acquired von Willebrand syndrome (AVWS), known to increase bleeding risk in moderate to severe PAH (33), and prophylactic von Willebrand factor (VWF)-containing concentrate supplementation (in the presence of AVWS), may have contributed to the low rate of bleeding complications. This evidence concerns the gene VWF and acquired von willebrand syndrome.